ReviewPharmaceutical biology2026
Turmeric (
Review in Pharmaceutical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Beyond the Rhizome: Phytochemistry, Biological Activities, and Sustainable Utilization ofPharmaceuticals (Basel, Switzerland) · 2026Review
- Bioactive Constituents, Mechanisms, and Complementary Therapeutic Applications of Food-Medicine Continuum Materia Medica for Atherosclerosis Prevention and Treatment.Pharmaceuticals (Basel, Switzerland) · 2026Review
- 10-Hydroxy-2-decenoic Acid Suppresses Colorectal Cancer Progression by Inhibiting Wnt/β-Catenin Signaling and Promoting Apoptosis.Foods (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextTurmeric (
objectiveThis work provides a comprehensive overview of turmeric rhizome essential oil including an assessment of the composition of authentic oils, and commercial oils, and a review of safety and pharmacology. MATERIALS AND
methodsAuthentic samples from India (
resultsAuthenticated oils were primarily composed of turmerones. Sesquiterpenes were more abundant in the oil from ground material, whereas monoterpenes were more prevalent in the oil from fresh rhizomes. Most market samples also exhibited the large dominance of turmerones, with some showing compositional variability, dilution, or adulteration, including 4/25 samples containing adulteration markers. Toxicological studies indicate no genotoxicity or dermal toxicity, minimal systemic toxicity, and good tolerability in humans. The pharmacology data supports anti-inflammatory, antimicrobial, neuroprotective, antioxidant, and anticancer properties, with synergistic effects when turmerones and curcuminoids are combined. DISCUSSION AND
conclusionTurmeric rhizome essential oil demonstrated a favorable safety profile and diverse bioactivities with therapeutic potential. However, compositional variation in commercial products with adulteration highlights the need for production standards. Authentic and consistent essential oil composition is key to ensure reproducible research findings, validate therapeutic potential, guarantee safety and provide the desirable outcomes when used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.